<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310671</url>
  </required_header>
  <id_info>
    <org_study_id>C.I.PI17/0256</org_study_id>
    <nct_id>NCT03310671</nct_id>
  </id_info>
  <brief_title>Aortic Stenosis in Subjects With Heterozygous Familial Hypercholesterolemia on Prolonged Treatment With Statins</brief_title>
  <official_title>Aortic Stenosis in Subjects With Heterozygous Familial Hypercholesterolemia on Prolonged Treatment With Statins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Aragones de Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Aragones de Ciencias de la Salud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aortic stenosis (AE) is a disease that has been increasing steadily in recent years in most&#xD;
      countries, including Spain.Risk factors for the development of AE include age,&#xD;
      hypercholesterolemia, diabetes mellitus and arterial hypertension, the classic risk factors&#xD;
      for the development of atherosclerosis. However, lipid-lowering therapy with statins and&#xD;
      ezetimibe has not been shown to reduce the risk of long-term progression of AE by unknown&#xD;
      mechanisms. All this suggests that subjects with HFhe have a high risk of developing AD,&#xD;
      which has not been shown by the high coronary mortality in this population that precedes&#xD;
      aortic calcification&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes a single clinical visit with collection of clinical data, blood extraction&#xD;
      and the performance of a transthoracic echocardiogram. This visit may be made on different&#xD;
      days, but always within 30 days of signing the informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Anticipated">July 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 18, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Differences in age-adjusted prevalence of EA assessed by transthoracic echocardiography between cases and controls</measure>
    <time_frame>1 YEAR</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in age-adjusted prevalence of AD assessed by transthoracic echocardiography between cases and controls</measure>
    <time_frame>1 YEAR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in aortic surface between cases and controls</measure>
    <time_frame>1 YEAR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the mean transvalvular gradient between cases and controls</measure>
    <time_frame>1 YEAR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between maximum aortic jet velocity between cases and controls</measure>
    <time_frame>1 YEAR</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Familial Hypercholesterolemia</condition>
  <condition>Conventional Transthoracic Echocardiogram</condition>
  <arm_group>
    <arm_group_label>CASES</arm_group_label>
    <description>Cases:&#xD;
Age ≥ 65 years at the time of cardiac ultrasound&#xD;
Genetically diagnosed HFH or in a first-degree relative&#xD;
History of hypercholesterolemia with LDLc levels&gt; 220 mg / dL without lipid-lowering treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Genetically Similar&#xD;
Siblings of the normocholesterolemic case, defined by LDLc &lt;190 mg / dl without lipid-lowering treatment.&#xD;
In the absence of available siblings, first cousins may be included.&#xD;
In the presence of several siblings available, the same sex will be included,&#xD;
Environmentally similar&#xD;
Stable partner of the case with cohabitation&gt; 25 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiogram</intervention_name>
    <description>Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve&#xD;
Pick up from:&#xD;
Mean transvalvular pressure gradient&#xD;
Aortic valve&#xD;
Aortic valve opening area&#xD;
Aortic valve opening area adjusted for body mass index&#xD;
Bicuspid or tricuspid aorta&#xD;
Thickness of the upper valve&gt; 3 mm</description>
    <arm_group_label>CASES</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Genetically diagnosed HFH or in a first-degree relative&#xD;
&#xD;
        - History of hypercholesterolemia with LDLc levels&gt; 220 mg / dL without lipid-lowering&#xD;
        treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cases:&#xD;
&#xD;
          -  Age ≥ 65 years at the time of cardiac ultrasound&#xD;
&#xD;
          -  Genetically diagnosed HFH or in a first-degree relative&#xD;
&#xD;
          -  History of hypercholesterolemia with LDLc levels&gt; 220 mg / dL without lipid-lowering&#xD;
             treatment&#xD;
&#xD;
        Controls:&#xD;
&#xD;
          -  Genetically Similar&#xD;
&#xD;
          -  Siblings of the normoccholesterolemic case, defined by LDLc &lt;190 mg / dl without&#xD;
             lipid-lowering treatment.&#xD;
&#xD;
          -  In the absence of available siblings, first cousins may be included.&#xD;
&#xD;
          -  In the presence of several siblings available, the same sex will be included,&#xD;
&#xD;
          -  Environmentally similar&#xD;
&#xD;
          -  Stable partner of the case with cohabitation&gt; 25 years * Each case will have at least&#xD;
             one control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Personal history of cardiac rheumatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fernando Civeira</last_name>
    <phone>976765500</phone>
    <phone_ext>2884</phone_ext>
    <email>civeira@unizar.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fernando Civeira Murillo</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria MARCO BENEDÍ, RD</last_name>
      <phone>976765500</phone>
      <phone_ext>2895</phone_ext>
      <email>vmarcobenedi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Aragones de Ciencias de la Salud</investigator_affiliation>
    <investigator_full_name>Fernando Civeira</investigator_full_name>
    <investigator_title>Instituto Aragonés de Ciencias de la Salud</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

